Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Authors:
- Yi-Long WuYWYi-Long Wu
- Jin Soo LeeJLJin Soo Lee
- Sumitra ThongprasertSTSumitra Thongprasert
- Chong-Jen YuCYChong-Jen Yu
- Li ZhangLZLi Zhang
- Guia LadreraGLGuia Ladrera
- Vichien SrimuninnimitVSVichien Srimuninnimit
- Virote SriuranpongVSVirote Sriuranpong
- Jennifer Sandoval-TanJSJennifer Sandoval-Tan
- Yunzhong ZhuYZYunzhong Zhu
- Meilin LiaoMLMeilin Liao
- Caicun ZhouCZCaicun Zhou
- 1 July 2013
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 14 (8) , 777-786
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysisJournal of Hematology & Oncology, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)British Journal of Cancer, 2012
- A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)Journal of Clinical Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004